- Home
- RNXT vs DYAI Comparison
RNXT vs DYAI Comparison
Compare RNXT & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNXT | DYAI |
|---|---|---|
| Founded | 2012 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0M | 30.8M |
| IPO Year | 2021 | 2003 |
Fundamental Metrics
Financial Performance| Metric | RNXT | DYAI |
|---|---|---|
| Price | $0.91 | $0.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $8.00 | $3.00 |
| AVG Volume (30 Days) | ★ 456.3K | 101.5K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,123,000.00 | ★ $3,090,345.00 |
| Revenue This Year | $267.59 | $131.04 |
| Revenue Next Year | $307.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2511.63 | N/A |
| 52 Week Low | $0.70 | $0.65 |
| 52 Week High | $1.45 | $1.35 |
Technical Indicators
Market Signals| Indicator | RNXT | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 57.66 |
| Support Level | $0.79 | $0.78 |
| Resistance Level | $1.07 | $0.97 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 7.65 | 69.07 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.